Prostate Cancer (Adenocarcinoma) clinical trials

Early PSA levels after prostate surgery and cancer outcomes

This study looks at how PSA (a blood marker) levels measured shortly after prostate removal surgery can predict whether cancer comes back. Researchers hope this helps doctors identify patients who may need closer monitoring or additional treatment after surgery.

Predicting cancer return and bladder control after robot prostate surgery

This study looks at factors that can predict whether prostate cancer will come back in the 10 years after robot-assisted prostate removal surgery, and how well bladder control (urinary continence) recovers. It helps doctors understand which patients might do better long-term.

Study of new drugs for advanced prostate cancer

This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.

Testing a new drug for metastatic prostate cancer

This trial tests an investigational drug (AZD0516) alone or with other treatments in men with prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy. It aims to see if the drug can help control the cancer.

A study of HLD-0915 for metastatic prostate cancer

This trial tests a new drug called HLD-0915 in men with prostate cancer that has spread. It aims to see how well the drug works and if it's safe.

Lu-PSMA before prostate surgery for high-risk cancer

This trial tests a treatment called Lu-177-PSMA-617 given before surgery for high-risk prostate cancer that has spread only to nearby lymph nodes. It aims to see if this approach helps control the cancer before the prostate is removed.

Using MRI to find prostate tumors

This study uses advanced MRI scans to better identify prostate cancer lesions before biopsy or surgery. It may help men who already have suspicious MRI findings and are scheduled for a prostate biopsy or removal.

Encorafenib + Cetuximab with FOLFIRI after progression

This trial tests adding a new chemotherapy regimen (FOLFIRI) to the combination of Encorafenib and Cetuximab for people with a specific type of advanced colorectal cancer that has started growing again after initial treatment with Encorafenib and Cetuximab. The goal is to see if the new combination can help control the cancer longer.

Talazoparib and enzalutamide for advanced prostate cancer after prior treatment

This trial tests a combination of two drugs, talazoparib and enzalutamide, in men with advanced prostate cancer that has progressed after previous treatment with a hormone therapy called an AR inhibitor. It aims to see if this combination can help control the cancer and delay further progression.

Dual PET scans for advanced prostate cancer

This study tests whether two kinds of PET scans, one targeting PSMA and one targeting sugar uptake (FDG), can help doctors better understand advanced prostate cancer. If you have prostate cancer that has spread (metastatic) and still responds to hormone therapy, the scans may help guide your treatment.

A new cell therapy for advanced prostate cancer

This trial tests a new cell therapy (AZD0754) for metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It’s looking for people whose cancer has gotten worse despite prior treatments, and who are still in fairly good health.

Testing a new radiation therapy for advanced prostate cancer

This trial tests a new radioactive drug, 225Ac-PSMA-Trillium, that targets prostate cancer cells. It is for people whose advanced prostate cancer has stopped responding to hormone therapy and may have spread.

Study of ADI-PEG20 with chemo for aggressive prostate cancer

This study tests a combination of three drugs—ADI-PEG20, carboplatin, and cabazitaxel—in men with aggressive variant prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination can shrink or slow the cancer.

Adenosine blocker plus immunotherapy for limited prostate spread

This Phase 2 study tests a medicine that affects “adenosine” signaling along with an immune checkpoint inhibitor (immunotherapy) in men with hormone-sensitive prostate cancer that has spread in only a small, limited way. It aims to stop or slow that limited spread by helping the immune system work better.

High-dose testosterone for prostate cancer with certain gene changes

This trial tests whether high doses of testosterone, a male hormone, can help slow or shrink prostate cancer that has stopped responding to usual hormone treatments, specifically in people whose tumors have changes in the ATM, CDK12, or CHEK2 genes.

Carbon ion radiation guided by scans for prostate cancer

This Phase 2 trial tests whether using detailed scans (PSMA PET/CT and MRI) to guide carbon ion radiation—delivered in a focused way—can treat localized prostate cancer. It may help target the treatment more precisely while avoiding areas that are not involved.

PSMA PET scan to guide lymph node surgery in prostatectomy

This study tests whether a special prostate scan called PSMA PET/CT can help doctors decide which pelvic lymph nodes to remove during prostate surgery. It may improve who needs lymph node surgery by using scan results to guide the operation.

Immunotherapy plus a targeted drug for rare genitourinary tumors

This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.

Blood tests to predict treatment response in prostate cancer

This study checks whether certain blood markers can help predict how well people with prostate cancer will respond to therapy. It may help doctors choose the most effective treatment sooner by using information from your blood.

Urine tests to predict outcomes in prostate cancer treatment

This study looks for urine markers (proteins and metabolites) that may help predict how prostate cancer patients respond to treatment and what their outcomes are. You may be asked to give a urine sample and allow use of your medical and treatment details for analysis (results are not shared with you).

Study of DEC003M for advanced prostate cancer

This trial tests a new targeted therapy (DEC003M) for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to see if this treatment is safe and helps shrink tumors.

Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Early-stage study of AZD8359 for advanced prostate cancer

This study tests a new experimental drug (AZD8359) designed to target prostate cancer cells in men whose cancer has progressed despite previous treatments. The drug works by directing immune cells to attack cancer cells.

High-dose radiation therapy for high-risk prostate cancer

This trial tests whether giving a higher dose of radiation therapy (called SBRT) can safely and effectively treat high-risk prostate cancer that hasn't spread. It's for men who have not yet been treated for their cancer.